Zyprexa & Risperdal 2: The Breast Cancer Link That Could Ignite the Next Mass Tort

by Fadi Agour | May 9, 2025

The pharmaceutical litigation landscape has seen its share of blockbuster cases—from opioid multidistrict litigations to the ongoing Paraquat Parkinson’s claims. But a new California lawsuit (Brown v. Johnson & Johnson et al.) could revive two legacy antipsychotics with a startling twist: breast cancer allegations tied to prolactin elevation.

The Plot Twist: From Gynecomastia to Oncology

For decades, Risperdal (J&J) and Zyprexa (Eli Lilly) faced litigation over metabolic and endocrine side effects—gynecomastia in boys, diabetes in long-term users. But plaintiff Bridgett Brown’s complaint, filed by Wisner Baum in Los Angeles Superior Court, alleges something darker: that these drugs’ prolactin-spiking mechanisms accelerated her breast cancer development.

The science behind this isn’t speculative. A 2023 JAMA Oncology study of 540,000 women linked high-prolactin antipsychotics to a 62% increased breast cancer risk (New York Times coverage). A 2025 meta-analysis in The Lancet pooled data from 15 studies, confirming a 59% risk hike(Washington Post summary). Even the NIH’s National Cancer Institute acknowledges prolactin’s role in tumor progression via the JAK-STAT5 pathway (NIH study).

Why This Theory Has Teeth

Off-Label Use = Broader Plaintiff PoolUnlike historic antipsychotic cases (focused on schizophrenia patients), this targets women prescribed these drugs for insomnia, dementia, or mood disorders—a demographic The Chicago Tribune notes now outnumbers psychiatric users (2024 investigation).

Documented Corporate KnowledgeInternal memos cited in the complaint suggest Lilly and J&J debated prolactin risks as early as 1991but omitted warnings. Sound familiar? It’s the same “playbook” CNN exposed in opioid litigation (2023 report).

Built-In Jury AppealBreast cancer carries visceral weight. As The Atlantic reported, jurors award 300% higher damages in oncology cases versus metabolic claims (2022 analysis).

The Mass Tort Potential

How to Position Your Firm

1. Mine Existing Intakes

2. Revisit old Risperdal/Zyprexa cases—especially those involving off-label prescriptions or female patients under 50.

3. Screen for Key Criteria

Prolactin levels > 100 ng/mL (per Annals of Internal Medicine thresholds)

ER+ breast cancer diagnoses (most prolactin-sensitive subtype)

Duration > 6 months

4. Partner with Specialists

5. Our team at Best Case Leads has already deployed:

AI-powered medical record review to flag prolactin labs

Non-incentivized intake protocols (no “bonus-driven” false claims)

Oncologist-consulted case scoring

The Best Case Leads Advantage

While others chase volume, we focus on compensable case quality:

Don’t wait for the JPML hearing. The first 50 screened cases get free viability scoring.
Contact us today at 877-795-2953 before this escalates into the next billion-dollar MDL.

Explore More Articles

Why Law Firms Lose the Cases They Already Paid For: 6 Foundation Gaps We See From the Other Side

Marketing agencies write about law firm growth from the outside looking in. We have a different vantage point. Best Case Leads delivers exclusive personal injury leads to law firms across the country, which means we watch the same product, a real injured claimant...

Bicycle Crash Claims: What Personal Injury Firms Need to Know About Liability, Evidence, and Intake

In 2024, 1,103 cyclists were killed and an estimated 52,887 were injured in U.S. traffic crashes, according to the National Highway Traffic Safety Administration. For plaintiff firms, those crashes produce some of the most serious injuries in the motor vehicle docket...

The Jealous Mistress Was Always a Bad Business Model: A Growth Framework for Solo and Small Personal Injury Firms

The Jealous Mistress Was Always a Bad Business Model: A Growth Framework for Solo and Small Personal Injury Firms Justice Story's line about the law demanding "lavish homage" has been quoted to every law student for two centuries. It produced a profession with...

Nearly Half of Law Firms Cannot Be Reached by Phone. The Problem Is Not Marketing. It Is the Empty Chair Next to the Owner.

In 2024, Clio commissioned a secret-shopper study of American law firms. Researchers posed as prospective clients and contacted 500 firms by phone and email. The results, published in the 2024 Legal Trends Report, were unambiguous. Only 40 percent of firms answered...

The Trial Lawyer Who Never Tries a Case: How to Grow a Personal Injury Firm Without Losing the Only Leverage That Matters

In 1990, federal district courts completed 4,765 civil jury trials. In 2025, according to the Administrative Office of the U.S. Courts, they completed 1,048, a decline of 10 percent in a single year and roughly 78 percent over the generation. The state courts, where...

Best Case Leads Celebrates Sixth Consecutive Year on Inc. 5000 List of Fastest-Growing Private Companies in America

Aug 19, 2025 | Press Releases Houston, TX, August 18, 2025 — Best Case Leads, a pioneering leader in legal lead generation, proudly announces its sixth consecutive recognition on the prestigious Inc. 5000 fastest-growing private companies in America, securing...

Baby Formula Litigation, NEC Claims, and the Evolving Landscape of Mass Torts

By Fadi Agour, J.D. Families of premature infants who developed necrotizing enterocolitis (NEC) after being fed cow–milk–based formula products like Similac and Enfamil continue to pursue justice in both state and federal courts. Recent...

Mass Tort Landscape 2025: Key Cases, Trends & Strategic Opportunities

The mass tort landscape is evolving rapidly, with new cases gaining momentum and established litigations reaching critical phases. For law firms and legal marketers, timing is everything—success hinges on anticipating trends, securing high-value claimants early, and...